Written from inside the Dutch life science scene. Joël is a Dutch marketer, working with biotech and life science companies across the Netherlands, Southeast Asia, and beyond.
Biotech marketing in the Netherlands works best when it starts from the science and builds commercial communication outward, because the audiences a Dutch life science company needs to reach (investors, partners, procurement leads, and scientific buyers) rarely respond to generic B2B messaging. The Netherlands holds one of Europe’s densest life sciences clusters, with hubs in Leiden, Amsterdam, Utrecht, and Oss, and a company here is usually competing for attention in an international market where English is the working language. That combination shapes how marketing should be planned, who it should speak to, and what kind of support is worth paying for.
Key takeaway: Effective biotech marketing in the Netherlands depends on translating credible science into commercial relevance for investor, partner, and scientific-buyer audiences that are usually international, not on local visibility alone.
Why does biotech marketing in the Netherlands look different?
Biotech marketing in the Netherlands looks different from generic B2B marketing because the Dutch life sciences ecosystem is unusually collaborative, internationally oriented, and concentrated around a few well-defined hubs. Leiden and Oss are established biopharmaceutical clusters, Utrecht Science Park anchors the centre of the country, and Amsterdam has grown as a life sciences base since the European Medicines Agency relocated there. The sector is represented nationally by HollandBIO, the Dutch biotech industry association, and coordinated through Health~Holland, the public-private Top Sector for Life Sciences and Health. The Netherlands supports biotechnology across medical, agrifood, and industrial applications, which means a general marketing approach will miss a large part of the market.
The practical consequence is that a company based here is rarely marketing to a purely domestic audience. It is usually raising from international investors, courting partners abroad, and selling into procurement processes that run through Europe. Marketing that only works for one of those audiences tends to underperform with the others, and that reality is what should drive the plan.
Strategy note: In biotech, the same message often has to convince a scientific reviewer, an international investor, and a procurement lead in the same quarter, so messaging that satisfies only one of them tends to stall the other two.
What do Dutch life science companies actually need from marketing?
Most Dutch life science companies need marketing that fixes positioning and messaging first, then builds the website, materials, and demand generation on top of a message that already holds up to scientific review. The common gap is familiar: the science is credible and the differentiation is real, but the language on the website and in the deck was written by and for experts rather than for the investors or customers the company is now trying to reach. Closing that gap is not a matter of flattening the science. It is a matter of framing it in terms of commercial relevance and the specific questions a sophisticated non-scientist audience is trying to answer.
In practice that usually means starting with positioning and messaging, setting it inside a broader biotech marketing strategy, and only then investing in a website and in digital marketing that carry the message to the right people. Spending on channels before the message is sound is the most common way Dutch biotech and biotechnology companies waste budget.
Should you hire a generalist agency or a life science specialist?
A life science company in the Netherlands is usually better served by a specialist agency that understands scientific buyers than by a generalist agency, because the differentiation that matters is technical and the sales cycle is long. A generalist can produce polished campaigns, but it tends to treat the science as a list of features and to optimise for fast conversion in a market where purchase decisions take months and involve several stakeholders. The table below sets out where the two approaches diverge.
| Dimension | Generalist marketing agency | Specialist life science agency |
|---|---|---|
| Understanding of the science | Treats the science as a feature list | Starts from scientific differentiation |
| Audience framing | One buyer persona | Investors, partners, procurement leads, scientific buyers |
| Sales cycle assumed | Optimised for fast conversion | Built for long technical B2B cycles |
| Message credibility | Holds up to marketing review | Holds up to scientific and marketing review |
| Typical first move | Launch broad campaigns | Fix positioning, then build outward |
Location matters less than fit. Because English is the working language of Dutch life sciences, a specialist agency does not need to sit in Leiden or Amsterdam to be useful; it needs to understand assay development, instrument evaluation, procurement cycles, and the way investors and scientific buyers actually read a claim.
Great biotech marketing does not simplify the science, it reveals why the science matters.
How does the Dutch biotech ecosystem shape go-to-market?
The concentrated Dutch biotech ecosystem shapes go-to-market by rewarding companies that can collaborate across academia, industry, and investors, which puts a premium on messaging that works across all three audiences at once. Public-private partnership is embedded in how the sector operates, from accelerator routes to the way the Netherlands positions itself internationally as a connected life sciences hub. For a therapeutics company that shows up as pipeline, indication, and partnering language aimed at a Series A or a partnering conversation. For a scientific instrument company, a CRO, a CDMO, or a diagnostics firm, it shows up as application notes, technical validation, and workflow-integration messaging aimed at procurement leads and scientific buyers. Science companies that sell tools or services need marketing that respects how their buyers evaluate, which is rarely on specifications alone.
How should a Netherlands-based biotech approach its marketing?
A Netherlands-based biotech should approach marketing as an ordered sequence that begins with audience and positioning and ends with demand generation, so that each layer rests on a message that is already commercially sound. The order is what protects the budget: assets and campaigns built on an unresolved message have to be redone once the message is fixed.
A sequence for biotech marketing in the Netherlands: four layers, built in order.
- Map the audiences you actually need to reach (investors, partners, procurement leads, scientific buyers) and what each one is trying to decide.
- Fix positioning and messaging so the science reads as commercial relevance, not only capability.
- Build the assets on that message: website, pitch deck, application notes, and marketing materials.
- Turn on demand generation (content, LinkedIn, targeted advertising) once the message and the assets are ready.
What this means for biotech and life science marketing in the Netherlands
Biotech marketing rewards companies that treat scientific credibility and commercial communication as one problem rather than two. The ecosystem is strong, the audiences are international, and the working language is English, so the advantage goes to companies whose message is specific, holds up to scientific review, and still lands with investors and buyers who are not scientists. That is achievable for a small company without a large in-house team, provided the work is done in the right order and by people who understand the science as well as the market.
Working through how to position your Dutch biotech for investors, partners, and scientific buyers? Biond works with life science and biotechnology companies in the Netherlands to turn credible science into commercial communication that holds up to both scientific and marketing review.
Frequently Asked Questions
Biotech marketing in the Netherlands is shaped by a dense, collaborative, and internationally oriented life sciences ecosystem, so specialist agency like Biond treats the audience as inherently international from the start. Companies in hubs such as Leiden, Amsterdam, Utrecht, and Oss usually raise from foreign investors and sell into English-language procurement processes, which means the message has to work for investors, partners, and scientific buyers at once rather than for a domestic market alone.
Biond finds that specialist understanding of scientific buyers matters more than a local address, because English is the working language of Dutch life sciences and the sales cycle is technical rather than geographic. A specialist that understands assay development, instrument evaluation, and procurement cycles can support a company in Leiden or Amsterdam as effectively as one nearby, provided it grasps how investors and scientific buyers actually read a claim.
Biond recommends that a Dutch life science startup resolve positioning and messaging before investing in channels, so that the website, deck, and demand generation all rest on a message that already holds up to scientific or investor review. Spending on advertising or content while the underlying message still reads like a feature list is the most common way early-stage biotech and biotechnology companies waste budget and have to redo the work later.
Yes, and Biond works with scientific instrument companies, CROs, CDMOs, diagnostics firms, and research service providers alongside therapeutics companies. For these businesses the buyer usually evaluates on workflow fit, technical validation, and risk rather than headline specifications, so the marketing centres on application notes, procurement realities, and integration into existing scientific workflows rather than on pipeline and indication language.